[The relation between myelotoxicity and performance status or aging in chemotherapy of non-small cell lung cancer]

F Oshita; T Shinkai; T Miya; A Kojima; Y Ohe; T Tamura; Y Sasaki; K Eguchi; N Saijo

[The relation between myelotoxicity and performance status or aging in chemotherapy of non-small cell lung cancer]

Nihon Kyobu Shikkan Gakkai Zasshi. 1991 Feb;29(2):231-8.

[Article in Japanese]

Authors

F Oshita¹, T Shinkai, T Miya, A Kojima, Y Ohe, T Tamura, Y Sasaki, K Eguchi, N Saijo

Affiliation

¹ Department of Internal Medicine, National Cancer Center Hospital, Tokyo.

PMID: 1851904

Abstract

One hundred eighty six patients of non-small cell lung cancer treated with cisplatin-based chemotherapy were analyzed. Significant incidence of anemia was observed in PS 2-3 patients as compared to PS 0-1 cases. Incidence of thrombocytopenia was significant in cases 70 or more years old as compared those less than 50 years old. No correlation was detected between myelotoxicity and aging.

Publication types

English Abstract

MeSH terms

Aged
Aged, 80 and over
Aging*
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bone Marrow / drug effects*
Carcinoma, Non-Small-Cell Lung / blood
Carcinoma, Non-Small-Cell Lung / drug therapy*
Cisplatin / administration & dosage
Cisplatin / adverse effects*
Female
Humans
Lung Neoplasms / blood
Lung Neoplasms / drug therapy*
Male
Middle Aged
Mitomycin
Mitomycins / administration & dosage
Thrombocytopenia / chemically induced*
Vindesine / administration & dosage

Substances

Mitomycins
Mitomycin
Cisplatin
Vindesine